Details for Patent: 8,183,295
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,183,295 protect, and when does it expire?
Patent 8,183,295 protects AMTURNIDE and is included in one NDA.
This patent has thirty-two patent family members in twenty-four countries.
Summary for Patent: 8,183,295
Title: | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
Abstract: | The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease. |
Inventor(s): | Feldman; David L (Teaneck, NJ), Webb; Randy L (Flemington, NJ) |
Assignee: | Novartis Pharmaceuticals Corporation (East Hanover, NJ) |
Application Number: | 12/188,604 |
Patent Claim Types: see list of patent claims | Composition; |
Drugs Protected by US Patent 8,183,295
International Family Members for US Patent 8,183,295
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 520417 | See Plans and Pricing | |||
Australia | 2003240669 | See Plans and Pricing | |||
Brazil | 0310084 | See Plans and Pricing | |||
Canada | 2485081 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |